148 related articles for article (PubMed ID: 18569785)
1. Synthesis and antitumor activity of a heterodinucleotide of BVDU and gemcitabine.
Cappellacci L; Franchetti P; Vita P; Petrelli R; Grifantini M
Nucleosides Nucleotides Nucleic Acids; 2008 May; 27(5):460-8. PubMed ID: 18569785
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
Wu W; Sigmond J; Peters GJ; Borch RF
J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.
Naguib YW; Lansakara-P D; Lashinger LM; Rodriguez BL; Valdes S; Niu M; Aldayel AM; Peng L; Hursting SD; Cui Z
Neoplasia; 2016 Jan; 18(1):33-48. PubMed ID: 26806350
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
Lansakara-P DS; Rodriguez BL; Cui Z
Int J Pharm; 2012 Jun; 429(1-2):123-34. PubMed ID: 22425885
[TBL] [Abstract][Full Text] [Related]
5. Macromolecular bipill of gemcitabine and methotrexate facilitates tumor-specific dual drug therapy with higher benefit-to-risk ratio.
Das M; Jain R; Agrawal AK; Thanki K; Jain S
Bioconjug Chem; 2014 Mar; 25(3):501-9. PubMed ID: 24506698
[TBL] [Abstract][Full Text] [Related]
6. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
Tsukagoshi S
Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
[TBL] [Abstract][Full Text] [Related]
7. A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-
Sun Y; Wang J; Hao K
Molecules; 2020 May; 25(9):. PubMed ID: 32397338
[TBL] [Abstract][Full Text] [Related]
8. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
[TBL] [Abstract][Full Text] [Related]
9. Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy.
Wang Q; Zhu X; Wu Z; Sun T; Huang W; Wang Z; Ding X; Jiang C; Li F
J Mater Chem B; 2020 Mar; 8(12):2410-2417. PubMed ID: 32100811
[TBL] [Abstract][Full Text] [Related]
10. Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivatives.
Peters GJ; Voorn DA; Kuiper CM; van der Wilt CL; Noordhuis P; Smid K; Myhren F; Sandvold M; Hendriks HR
Nucleosides Nucleotides; 1999; 18(4-5):877-8. PubMed ID: 10432699
[TBL] [Abstract][Full Text] [Related]
11. A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
Guenther S; Balzarini J; De Clercq E; Nair V
J Med Chem; 2002 Dec; 45(25):5426-9. PubMed ID: 12459010
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
Herdewijn P; De Clercq E; Balzarini J; Vanderhaeghe H
J Med Chem; 1985 May; 28(5):550-5. PubMed ID: 2985782
[TBL] [Abstract][Full Text] [Related]
13. A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms.
Alexander RL; Greene BT; Torti SV; Kucera GL
Cancer Chemother Pharmacol; 2005 Jul; 56(1):15-21. PubMed ID: 15789226
[TBL] [Abstract][Full Text] [Related]
14. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic.
Bookman MA
Int J Gynecol Cancer; 2005; 15 Suppl 1():12-7. PubMed ID: 15839953
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine).
Grindey GB; Hertel LW; Plunkett W
Cancer Invest; 1990; 8(2):313. PubMed ID: 2400957
[No Abstract] [Full Text] [Related]
17. Cell-specific activation of gemcitabine by endogenous H
Maiti M; Yoon SA; Cha Y; Athul KK; Bhuniya S; Lee MH
Chem Commun (Camb); 2021 Sep; 57(75):9614-9617. PubMed ID: 34486009
[TBL] [Abstract][Full Text] [Related]
18. Radiation enhancement by gemcitabine-mediated cell cycle modulations.
Mose S; Class R; Weber HW; Rahn A; Brady LW; Böttcher HD
Am J Clin Oncol; 2003 Feb; 26(1):60-9. PubMed ID: 12576927
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma.
Stephenson AA; Cao S; Taggart DJ; Vyavahare VP; Suo Z
Eur J Med Chem; 2021 Mar; 213():113135. PubMed ID: 33454548
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells.
Graziadei I; Kelly T; Schirmer M; Geisen FH; Vogel W; Konwalinka G
J Hepatol; 1998 Mar; 28(3):504-9. PubMed ID: 9551690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
